New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareChonluten vs VIP

Chonluten vs VIP

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Chonluten
Immune SupportSleep Optimization
VIP
Summary
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
Half-Life
Short (minutes for the peptide); sustained gene-regulatory effects
~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
Admin Route
SubQ, Oral
Intranasal, SubQ, IV
Research
Typical Dose
10 mg per day
50 mcg (4 sprays of 12.5 mcg each)
Frequency
Daily for 10–30 days
4x daily
Key Benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
  • Potent anti-inflammatory for CIRS and mold illness
  • Improves pulmonary hypertension symptoms
  • Regulates gut motility and IBS symptoms
  • Modulates circadian rhythm and sleep quality
  • Reduces mast cell activation (MCAS)
  • Improves cognitive function in neuroinflammatory conditions
  • Vasodilatory — reduces vascular resistance
Side Effects
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
  • Facial flushing (transient, intranasal)
  • Mild nausea
  • Headache at initiation
  • Hypotension at high doses
  • +1 more
Stacks With